Related Experiment Videos
Differences between responsive and intractable chronic lymphocytic leukemia.
1Research Service, VA Hospital, Hines, IL 60141.
Medical Hypotheses
|February 1, 1990
Summary
Approximately 19-26% of chronic lymphocytic leukemia (CLL) patients have intractable disease resistant to chemotherapy. This intractable CLL is a proliferative disease, unlike the accumulative, responsive form.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- Chronic lymphocytic leukemia (CLL) presents in approximately 19-26% of patients with a chemotherapy-resistant, intractable form.
- Intractable CLL is associated with a shorter median survival time compared to responsive forms.
- Patients with intractable CLL often show responsiveness to splenectomy.
Purpose of the Study:
- To differentiate between responsive and intractable chronic lymphocytic leukemia (CLL).
- To investigate the distinct biological characteristics of intractable CLL.
- To identify potential therapeutic strategies for intractable CLL.
Main Methods:
- In vitro assessment of lymphocyte resistance to X-irradiation and colchicine in patients with intractable CLL.
- Comparative analysis of disease behavior: accumulative (responsive) versus proliferative (intractable).
Main Results:
- Lymphocytes from patients with intractable CLL demonstrated in vitro resistance to X-irradiation and colchicine.
- Intractable CLL was characterized as a proliferative disease.
- Responsive CLL was characterized as an accumulative disease.
Conclusions:
- Intractable chronic lymphocytic leukemia exhibits distinct cellular resistance and proliferative characteristics.
- These findings suggest different underlying mechanisms for responsive and intractable CLL.
- Understanding these differences may guide future treatment strategies for chemotherapy-resistant CLL.